- Home
- UHG vs ACIU Comparison
UHG vs ACIU Comparison
Compare UHG & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHG
- ACIU
- Stock Information
- Founded
- UHG 2004
- ACIU 2003
- Country
- UHG United States
- ACIU Switzerland
- Employees
- UHG N/A
- ACIU N/A
- Industry
- UHG Homebuilding
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- UHG Consumer Discretionary
- ACIU Health Care
- Exchange
- UHG Nasdaq
- ACIU Nasdaq
- Market Cap
- UHG 281.1M
- ACIU 305.7M
- IPO Year
- UHG N/A
- ACIU 2016
- Fundamental
- Price
- UHG $6.10
- ACIU $3.38
- Analyst Decision
- UHG
- ACIU Strong Buy
- Analyst Count
- UHG 0
- ACIU 2
- Target Price
- UHG N/A
- ACIU $12.00
- AVG Volume (30 Days)
- UHG 27.9K
- ACIU 132.6K
- Earning Date
- UHG 11-08-2024
- ACIU 11-05-2024
- Dividend Yield
- UHG N/A
- ACIU N/A
- EPS Growth
- UHG N/A
- ACIU N/A
- EPS
- UHG N/A
- ACIU N/A
- Revenue
- UHG $445,729,916.00
- ACIU $48,505,404.00
- Revenue This Year
- UHG N/A
- ACIU N/A
- Revenue Next Year
- UHG N/A
- ACIU $938.44
- P/E Ratio
- UHG N/A
- ACIU N/A
- Revenue Growth
- UHG 6.19
- ACIU 4097200.00
- 52 Week Low
- UHG $5.09
- ACIU $2.25
- 52 Week High
- UHG $9.48
- ACIU $5.14
- Technical
- Relative Strength Index (RSI)
- UHG 50.53
- ACIU 55.80
- Support Level
- UHG $5.82
- ACIU $3.16
- Resistance Level
- UHG $6.52
- ACIU $3.41
- Average True Range (ATR)
- UHG 0.48
- ACIU 0.24
- MACD
- UHG -0.02
- ACIU 0.03
- Stochastic Oscillator
- UHG 35.16
- ACIU 43.18
About UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.